KRAS and non-small cell lung carcinoma: In the CodeBreak 100/101 Phase Ib clinical trial, the efficacy of combining AMG 510 with Pembrolizumab or Atezolizumab was investigated in 58 patients with KRAS G12C-mutant NSCLC (21).